Composition for cell protection containing cyclo histidine-proline as active ingredient
Inventors
Jung, Hoe-Yune • Lee, Heon-Jong • Jeon, Jong-Su • Kim, Yon-Su • Yang, Seung-Hee • Kim, Yong-Chul • Moon, Jong-Joo • Yoo, Hwan-Soo • Choi, Kyeong-Mi
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11433114-B2
Publication Date
2022-09-06
Expiration Date
Abstract
A new use of a cyclo histidine-proline (Cyclo His-Pro, CHP) is disclosed. A composition including cyclo histidine-proline (CHP) as an active ingredient has an excellent protective effect to protect kidney and liver cells from damage and/or toxicity induced by various causes. The composition is useful and effective in protecting kidney and/or liver cells/tissues and in treating a subject with kidney and/or liver diseases and/or damages.
Core Innovation
The invention relates to cyclo histidine-proline (CHP) for cell protection by suppressing apoptosis of liver cells. It is described as a composition comprising cyclo histidine-proline (CHP) or its pharmaceutically acceptable salt as an active ingredient, and the administering is characterized by suppressing apoptosis of liver cells in a subject.
The problem addressed is drug-induced cellular damage associated with liver toxicity and liver cell damage, including liver disease states such as hepatic failure, acute hepatitis, chronic hepatitis, liver cirrhosis, hepatic coma, or alcoholic liver disease. The apoptosis of liver cells is stated to be caused by administration of a drug, and the invention is directed to suppressing that apoptosis.
The invention is also directed to inhibiting liver cell apoptosis in a subject in need thereof by administering an effective amount of the CHP composition where the subject suffers from liver damage, liver toxicity, and/or liver disease. The document further supports cell-protecting use in connection with drug administration and indicates both in vitro and in vivo results using drug-induced apoptosis models for kidney and liver cells.
Claims Coverage
The document includes three independent methods focused on CHP-based compositions that suppress apoptosis in liver cells caused by drug administration, covering liver diseases and liver toxicity contexts. Across the independent claims, there are two principal inventive aspects: administering an effective amount of a CHP or pharmaceutically acceptable salt composition, and suppressing drug-caused apoptosis of liver cells in specified subject contexts.
Chp composition for treating liver disease by suppressing apoptosis of liver cells
A method of treating a subject suffering from a liver disease, having liver cell damage, and/or suffering from liver toxicity, comprising administering an effective amount of a composition comprising cyclo histidine-proline (CHP) or its pharmaceutically acceptable salt as an active ingredient to the subject, wherein the administering suppresses apoptosis of liver cells, and wherein the liver disease is hepatic failure, acute hepatitis, chronic hepatitis, liver cirrhosis, hepatic coma, or alcoholic liver disease.
Chp composition for treating liver cell damage and drug-caused liver cell apoptosis
A method of treating a subject suffering from a liver disease, having liver cell damage, and/or suffering from liver toxicity, comprising administering an effective amount of a composition comprising cyclo histidine-proline (CHP) or its pharmaceutically acceptable salt as an active ingredient to the subject, wherein the administering suppresses apoptosis of liver cells, and wherein the apoptosis of liver cells is caused by administration of a drug.
Chp composition for inhibiting drug-caused liver cell apoptosis in subjects with liver damage
A method of inhibiting liver cell apoptosis in a subject in need thereof, comprising administering an effective amount of a composition comprising cyclo histidine-proline (CHP) or its pharmaceutically acceptable salt as an active ingredient, wherein the liver cell apoptosis is caused by administration of a drug, wherein the subject suffers from liver damage, liver toxicity, and/or liver disease, and wherein the liver disease is hepatic failure, acute hepatitis, chronic hepatitis, liver cirrhosis, hepatic coma, or alcoholic liver disease.
All independent claims center on administering a composition comprising cyclo histidine-proline (CHP) or its pharmaceutically acceptable salt to suppress apoptosis of liver cells, specifically where apoptosis is caused by administration of a drug, and where the subject has specified liver disease and/or liver toxicity.
Stated Advantages
Suppresses apoptosis of liver cells in subjects suffering from liver disease, liver cell damage, and/or liver toxicity.
Inhibits liver cell apoptosis caused by administration of a drug.
Reduces liver injury markers (ALT and AST) and kidney injury markers (creatinine and BUN) in mice challenged with cisplatin.
Documented Applications
Use as a cell-protecting pharmaceutical composition for preventing or ameliorating kidney and liver damage or diseases associated with drug-induced toxicity.
Use as a health functional food to prevent or ameliorate kidney and liver damage or diseases.
In vitro apoptosis inhibition showing suppression of gentamicin-induced kidney cell apoptosis (LLC-PK1) and acetaminophen-induced liver cell apoptosis (Chang liver cells).
In vivo reduction of liver injury markers (ALT, AST) and kidney injury markers (creatinine, BUN) in mice challenged with cisplatin.
Interested in licensing this patent?